In India, Zika detection test to hit market by March, cost pegged at Rs 5,000 Himani Chandnabusiness Updated: Feb 03, 2016 17:44 IST
Zika virus detection kits are likely to reach the market by March and cost around Rs 4500 to Rs 5000, leading diagnostic chains have said, amidst a spiraling global health crisis triggered by a viral outbreak linked to thousands of birth defects.
The country’s leading pathology labs and diagnostic chains including Dr Lal PathLabs, SRL Diagnostics, Quest Diagnostics and Star Imaging have started procuring test kits and discovering new technologies to detect the Zika virus.
On Tuesday, the World Health Organisation (WHO) declared the disease caused by a mosquito-borne virus an international health emergency.
There are no known cases of Zika in India yet though the government has issued an advisory asking expectant mothers to avoid travelling to affected countries, most of which are in Latin America.
Watch | WHO doctor says Zika vaccine likely “years away”
Dr Lal PathLabs, which was recently listed on the Bombay Stock Exchange, is ready to dole out a detection test for Zika virus by next month which would cost about Rs 4500, the company spokesperson said.
“Saliva or urine samples collected during the first three to five days after symptoms onset, or blood serum collected in the first three days, are suitable for detection of Zika virus,” the spokesperson said.
“We have had queries from hospitals based in Mumbai, Delhi as well as Sri Lanka as of now. We should be ready with the assay by mid-March as kits to perform tests would be available with us by first week of March.”
Dr BR Das, president, research and innovation, at SRL Diagnostics, the country’s largest and Asia’s second largest diagnostics chain as per volume of tests handled, said, “We will join hands with technology providers. For Zika virus detection, a blood test known as real-time polymerase chain reaction (PCR) is required and we are updating our information globally.”
However, Das refused to divulge details on estimated pricing.
American diagnostics major, Quest Diagnostics, circulated an internal document to its Indian offices last week saying that the “company is working around technology to detect Zika virus attack,” said an official requesting anonymity.
Delhi-based chain, Star Imaging & Path Lab, is tendering vendors to supply kits required for conducting tests and detecting viruses. “We have kicked off the process and it seems that the PCR test is the most valid as of now,” said Prabhjot Kaur Chopra, pathology department at Star Imaging.
French drug major Sanofi -- which owns an array of top vaccines for viruses in the same family as Zika virus -- has launched a Zika vaccine project to hunt for the most suitable vaccine on Tuesday.
“Our invaluable collaborations with scientific and public health experts, both globally and in the regions affected by the outbreaks of Zika virus, together with the mobilisation of our best experts will expedite efforts to research and develop a vaccine for this disease,” said Dr. John Shiver, Global Head of R&D, Sanofi Pasteur.
The world’s first dengue vaccine, from Sanofi, was approved in December after 20 years of research.